5-hydroxy-2-n-n-dipropylaminotetralin--(s)-isomer and Parkinson-Disease

5-hydroxy-2-n-n-dipropylaminotetralin--(s)-isomer has been researched along with Parkinson-Disease* in 2 studies

Other Studies

2 other study(ies) available for 5-hydroxy-2-n-n-dipropylaminotetralin--(s)-isomer and Parkinson-Disease

ArticleYear
Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists.
    Bioorganic & medicinal chemistry, 2016, 06-15, Volume: 24, Issue:12

    Aiming to discover dual-acting β2 adrenergic/dopamine D2 receptor ligands, a structure-guided approach for the evolution of GPCR agonists that address multiple targets was elaborated. Starting from GPCR crystal structures, we describe the design, synthesis and biological investigation of a defined set of compounds leading to the identification of the benzoxazinone (R)-3, which shows agonist properties at the adrenergic β2 receptor and substantial G protein-promoted activation at the D2 receptor. This directed approach yielded molecular probes with tuned dual activity. The congener desOH-3 devoid of the benzylic hydroxyl function was shown to be a β2 adrenergic antagonist/D2 receptor agonist with Ki values in the low nanomolar range. The compounds may serve as a promising starting point for the investigation and treatment of neurological disorders.

    Topics: Adrenergic beta-2 Receptor Agonists; Animals; Benzoxazines; CHO Cells; Cricetulus; Dopamine Agonists; Drug Discovery; HEK293 Cells; Humans; Models, Molecular; Parkinson Disease; Polypharmacology; Receptors, Adrenergic, beta-2; Receptors, Dopamine D2

2016
Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treat
    Journal of medicinal chemistry, 2015, Dec-10, Volume: 58, Issue:23

    Our structure-activity relationship studies with N(6)-(2-(4-(1H-indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine derivatives led to development of a lead compound (-)-21a which exhibited very high affinity (Ki, D2 = 16.4 nM, D3 = 1.15 nM) and full agonist activity (EC50 (GTPγS); D2 = 3.23 and D3 = 1.41 nM) at both D2 and D3 receptors. A partial agonist molecule (-)-34 (EC50 (GTPγS); D2 = 21.6 (Emax = 27%) and D3 = 10.9 nM) was also identified. In a Parkinson's disease (PD) animal model, (-)-21a was highly efficacious in reversing hypolocomotion in reserpinized rats with a long duration of action, indicating its potential as an anti-PD drug. Compound (-)-34 was also able to elevate locomotor activity in the above PD animal model significantly, implying its potential application in PD therapy. Furthermore, (-)-21a was shown to be neuroprotective in protecting neuronal PC12 from toxicity of 6-OHDA. This report, therefore, underpins the notion that a multifunctional drug like (-)-21a might have the potential not only to ameliorate motor dysfunction in PD patients but also to modify disease progression by protecting DA neurons from progressive degeneration.

    Topics: Animals; Antiparkinson Agents; Benzothiazoles; Cell Line; Drug Discovery; Female; Humans; Locomotion; Male; Neuroprotective Agents; Parkinson Disease; Piperazines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, Dopamine D3; Structure-Activity Relationship

2015